Search Results for "Drug Abuse"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Abuse. Results 61 to 70 of 125 total matches.
In Brief: Immediate-Release Oxycodone (Oxecta) for Pain
The Medical Letter on Drugs and Therapeutics • Mar 05, 2012 (Issue 1385)
causes burning and irritation. Whether the new formulation
will actually prevent abuse of the drug ...
The FDA has approved a new tablet formulation of immediate-release (IR) oxycodone (Oxecta – King) for management of acute and chronic moderate to severe pain.Oxecta uses a tamper-resistant technology designed to deter oxycodone abuse by injection or nasal snorting. Dissolving the crushed tablet in water or alcohol converts it into a viscous gel mixture, making it difficult to inject. Crushing the tablet and inhaling it through the nose causes burning and irritation. Whether the new formulation will actually prevent abuse of the drug has not been established. Oxecta is classified as a...
OTC Primatene Mist Returns
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019 (Issue 1564)
and
heart rate.
Misuse or abuse of the product by excessive inhalation
or IV injection of epinephrine ...
The FDA has approved over-the-counter (OTC) sale
of inhaled epinephrine (Primatene Mist – Amphastar),
a nonselective alpha and beta agonist, for temporary
relief of mild symptoms of intermittent asthma in
patients ≥12 years old who have been diagnosed with
mild intermittent asthma by a healthcare professional.
The original version of Primatene Mist, which was
approved by the FDA in 1967, was removed from the
market in 2011 because the metered-dose inhaler (MDI)
contained ozone-depleting chlorofluorocarbon (CFC)
propellants; the new MDI contains hydrofluoroalkane
(HFA)...
Eszopiclone (Lunesta), a New Hypnotic
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005 (Issue 1203)
and seizures, as well as numerous case reports
describing habituation and abuse of these drugs.
14,15,16 ...
Eszopiclone (Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone (Imovane, and others in Canada), which has been available in other countries for almost 20 years. Unlike similar drugs such as zolpidem (Ambien) or zaleplon (Sonata), Lunesta is not being restricted in its labeling to short-term use. Like other hypnotics, eszopiclone is a schedule IV drug.
Dextromethorphan/Bupropion (Auvelity) for Depression
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
being used off-label in patients with
treatment-resistant depression. Both drugs can
rapidly, though ...
The FDA has approved an extended-release fixed-dose
combination of dextromethorphan and
bupropion (Auvelity – Axsome) for treatment of major
depressive disorder (MDD) in adults.
Oxycodone OxyContin
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
.
DRUG DEPENDENCE AND ABUSE — Oxycodone is a Schedule II controlled substance
with a dependence ...
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Gamma Hydroxybutyrate (Xyrem) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Dec 09, 2002 (Issue 1145)
dependence and craving have been reported with abuse of the drug
in similar doses.
ADVERSE EFFECTS — GHB ...
The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB), a metabolite of gamma-aminobutyric acid (GABA), is a central-nervous-system depressant marketed in Europe for use in general anesthesia. In recent years it has been notorious for its use in "date-rape" (Medical Letter 2002; 44:21). Xyrem is a Schedule III controlled substance.
A Morphine/Naltrexone Combination (Embeda) for Pain
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
Drug dependence Dependence Combination drugs for pain Avinza Analgesics Addiction Abuse of morphine ...
The FDA has approved an agonist/antagonist combination of morphine and naltrexone (Embeda – King)
for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended
period of time. The addition of naltrexone is intended to prevent abuse of morphine.
Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
unpublished
abuse potential studies in recreational drug users
(summarized in the package insert ...
The FDA has approved eluxadoline (Viberzi – Actavis),
a mu-opioid receptor agonist and delta-opioid
receptor antagonist, for oral treatment of adults with
irritable bowel syndrome with diarrhea (IBS-D).
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
to
deter abuse of the drug by injection or snorting.
DRUG INTERACTIONS — Drugs that inhibit CYP3A4 ...
The FDA has approved a fixed-dose extended-release
formulation of oxycodone and acetaminophen
(Xartemis XR – Mallinckrodt) for oral treatment of
acute pain severe enough to require an opioid. Oxycodone
is available in the US as a single entity in oral
immediate-release (Oxecta, and others) and extendedrelease
(OxyContin) formulations. Immediate-release
oxycodone is also available in combination with aspirin
(Percodan, and others), acetaminophen (Percocet,
and others), or ibuprofen (see Table 1).
Extended-Release Hydrocodone (Zohydro ER) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
The Medical Letter®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 145 ...
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for which
alternative treatment options are inadequate. Zohydro ER
is the first single-ingredient hydrocodone product to be
marketed in the US. Hydrocodone has been available for
years in combination with acetaminophen (Vicodin, and
others) or ibuprofen (Vicoprofen, and others).